Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics


Eton Pharmaceuticals, Inc. (ETON)

Today's Latest Price: $5.40 USD

0.00 (0.00%)

Updated Feb 28 3:59pm

Add ETON to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ETON Stock Summary

  • ETON's went public 1.29 years ago, making it older than just 0.49% of listed US stocks we're tracking.
  • ETON's price/sales ratio is 262.12; that's higher than the P/S ratio of 98.91% of US stocks.
  • With a year-over-year growth in debt of -56.3%, Eton Pharmaceuticals Inc's debt growth rate surpasses merely 5.49% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Eton Pharmaceuticals Inc are FOMX, ADAP, CUE, AKTS, and GERN.
  • ETON's SEC filings can be seen here. And to visit Eton Pharmaceuticals Inc's official web site, go to www.etonpharma.com.
ETON Daily Price Range
ETON 52-Week Price Range

ETON Stock Price Chart More Charts


ETON Price/Volume Stats

Current price $5.40 52-week high $10.20
Prev. close $5.40 52-week low $5.11
Day low $5.15 Volume 44,100
Day high $5.44 Avg. volume 75,598
50-day MA $6.82 Dividend yield N/A
200-day MA $6.64 Market Cap 96.16M

Eton Pharmaceuticals, Inc. (ETON) Company Bio


Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.


ETON Latest News Stream


Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream


Loading social stream, please wait...

View Full ETON Social Stream

ETON Price Returns

1-mo -21.40%
3-mo -15.63%
6-mo -3.40%
1-year -31.65%
3-year N/A
5-year N/A
YTD -25.00%
2019 17.65%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.52 seconds.